Specifically, miR-181b, a regulator of B cell differentiation, is expressed at low levels in CLL cells [15], which at least partly determines high levels of its targets, the antiapoptotic proteins MCL1 and BCL2, and consequently the resistance to proapoptotic drugs [16,17]. The gene discussed is MCL1; the disease is B-cell chronic lymphocytic leukemia.